Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Enterprise Value (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Enterprise Value for 6 consecutive years, with -$75.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Enterprise Value rose 28.65% year-over-year to -$75.6 million, compared with a TTM value of -$75.6 million through Sep 2025, up 28.65%, and an annual FY2024 reading of -$112.3 million, down 53319.91% over the prior year.
  • Enterprise Value was -$75.6 million for Q3 2025 at Barinthus Biotherapeutics, up from -$87.7 million in the prior quarter.
  • Across five years, Enterprise Value topped out at $211000.0 in Q4 2023 and bottomed at -$243.1 million in Q2 2021.
  • Average Enterprise Value over 5 years is -$150.1 million, with a median of -$160.1 million recorded in 2023.
  • The sharpest move saw Enterprise Value tumbled 54733.5% in 2021, then soared 100.11% in 2023.
  • Year by year, Enterprise Value stood at -$213.6 million in 2021, then rose by 9.15% to -$194.1 million in 2022, then skyrocketed by 100.11% to $211000.0 in 2023, then crashed by 53319.91% to -$112.3 million in 2024, then soared by 32.7% to -$75.6 million in 2025.
  • Business Quant data shows Enterprise Value for BRNS at -$75.6 million in Q3 2025, -$87.7 million in Q2 2025, and -$100.5 million in Q1 2025.